Taylor Wessing, Ashurst and A&O Shearman advised on EpilepsyGTx’s US$33 million Series A funding.
EpilepsyGTx, a London-based biotechnology company focused on the development of gene therapies for refractory epilepsy, has raised US$33 million in its Series A funding round. The financing included investments from XGEN Venture, British Patient Capital and other strategic investors, and will support the advancement of the company’s lead programme, EPY201, as well as the commencement of a first-in-human Phase 1/2a clinical trial in the UK and Europe by the end of 2026.
Taylor Wessing advised EpilepsyGTx on the Series A financing. The transaction team comprised Partner Ross McNaughton, Senior Associate Bella Thornton-Clark, and Associate Phoebe Sennett.
Ashurst advised British Patient Capital on its investment in the funding round. The Ashurst team was led by Corporate Partner Jacob Gold and Senior Associate Dillon Fuzi, with support from Associate Elnaz Cadogan.
A&O Shearman acted as legal advisor to XGEN Venture in connection with its investment in EpilepsyGTx.
The deal reporting on this platform is based on the information received from law firms, and therefore, some details may be missing/incomplete. If your firm has not been credited for this deal, write to us at chanchal.makhija@thegreymatter.co.in mentioning your firm’s name, lawyers involved (including designation) and client represented.
